Precision Medicine

GuideAI Health's new AI platform just hit the public market. It promises to find hidden vascular disease in routine scans, but can it navigate the risks?

At the Global Dairy Congress, Yili Group didn't just win awards; it showcased a new future for dairy—one driven by precision nutrition and R&D.

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

A new blood test and a powerful partnership between a diagnostics firm and a patient foundation aim to end years of misdiagnosis for a rare lung disease.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.

A new partnership brings advanced, FDA-cleared HPV testing to the home. The true innovation, however, is the system built to overcome the last-mile problem.

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

The animal health leader faces scrutiny in its Q2 earnings call after a rocky first quarter. All eyes are on its strategy to balance market pressures with future-focused bets.

By combining vast datasets with patient-driven advocacy, a new alliance offers hope for angiosarcoma patients and a new model for rare disease research.

A new deal in Israel signals a shift from noisy, ineffective warnings to precise, life-saving insights. Is this the future of personalized medication safety?

As Abbott prepares its July 16th earnings report, all eyes are on more than just the balance sheet. It's a test of its post-acquisition strategy.

A Virginia nonprofit's AI platform, backed by Pentagon funding, has decoded the deadly impact of radiation on the gut, paving the way for new countermeasures.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Johnson & Johnson's new platform combines RF and PF ablation, moving beyond the hype of single-modality tech to offer physicians unprecedented versatility.

IBA's deal to build Brazil's first proton therapy center is more than a medical breakthrough; it's a high-stakes play for market dominance in Latin America.

A new ARPA-H grant aims to replace 50-year-old tech with a rapid blood test for fetal hypoxia, a move that could slash C-sections and save lives.

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.